KURA Kura Oncology, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Kura Oncology, Inc. (KURA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 5, 2026, a 10-Q quarterly report filed on November 4, 2025, an 8-K current report filed on March 5, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Kura Oncology, Inc. (KURA) (SEC CIK 1422143), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 5, 2026 — full figures in Exhibit 99.1
- • KURA is a clinical-stage oncology company; results likely reflect R&D spend, cash runway, and pipeline progress rather than product revenue
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Kura Oncology, Inc. (KURA) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 5, 2026 | — | Analysis | — |
10-K | Mar 5, 2026 | Dec 31, 2025 | — | |
8-K | Jan 29, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 2, 2025 | — | — | |
10-Q | Nov 4, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 1, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Feb 27, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 10, 2023 | Mar 31, 2023 | — | |
10-K | Feb 23, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 24, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-K | Feb 24, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest KURA SEC filings in 2026?
Kura Oncology, Inc. (KURA) has filed a 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 4, 2025, an 8-K current report on March 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did KURA file its most recent 10-K annual report?
Kura Oncology, Inc. (KURA) filed its most recent 10-K annual report on March 5, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view KURA 10-Q quarterly reports?
Kura Oncology, Inc. (KURA)'s most recent 10-Q quarterly report was filed on November 4, 2025. SignalX displays every KURA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has KURA filed recently?
Kura Oncology, Inc. (KURA)'s most recent 8-K was filed on March 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find KURA insider trading activity (Form 4)?
SignalX aggregates every KURA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does KURA file with the SEC?
Kura Oncology, Inc. (KURA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new KURA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Kura Oncology, Inc. (KURA).
What is KURA's SEC CIK number?
Kura Oncology, Inc. (KURA)'s SEC CIK (Central Index Key) number is 1422143. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1422143 to look up all KURA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find KURA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Kura Oncology, Inc. (KURA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Kura Oncology, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 72+ filings.